The estimated Net Worth of Brian Schlier is at least $540 Mille dollars as of 8 January 2008. Brian Schlier owns over 15,000 units of Artelo Biosciences Inc stock worth over $17,850 and over the last 19 years Brian sold ARTL stock worth over $521,887.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Brian Schlier ARTL stock SEC Form 4 insiders trading
Brian has made over 8 trades of the Artelo Biosciences Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently Brian exercised 15,000 units of ARTL stock worth $61,500 on 8 January 2008.
The largest trade Brian's ever made was exercising 15,000 units of Artelo Biosciences Inc stock on 8 January 2008 worth over $61,500. On average, Brian trades about 6,278 units every 95 days since 2005. As of 8 January 2008 Brian still owns at least 15,000 units of Artelo Biosciences Inc stock.
You can see the complete history of Brian Schlier stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Brian Schlier's mailing address?
Brian's mailing address filed with the SEC is 96 CUMMINGS POINT RD, , STAMFORD, CT, 06902.
Insiders trading at Artelo Biosciences Inc
Over the last 22 years, insiders at Artelo Biosciences Inc have traded over $1,017,062 worth of Artelo Biosciences Inc stock and bought 94,621 units worth $215,565 . The most active insiders traders include Connie Matsui, Steven B Lapin e Georgia Erbez. On average, Artelo Biosciences Inc executives and independent directors trade stock every 89 days with the average trade being worth of $13,026. The most recent stock trade was executed by Gregory D. Gorgas on 12 August 2022, trading 1,200 units of ARTL stock currently worth $4,800.
What does Artelo Biosciences Inc do?
artelo biosciences is a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class science to accelerate the development and commercialization of a diverse portfolio of novel, endocannabinoid system modulating therapeutics. our programs have the potential to dramatically improve patient care in major markets. with our headquarters team in san diego, california, usa and our european office in dublin, ireland, artelo established a presence in key global biopharma innovation hubs with close access to world-class research expertise. artelo’s research and development leverages the skill, knowledge and experience of our collaboration partners in europe and north america.
What does Artelo Biosciences Inc's logo look like?
Complete history of Brian Schlier stock trades at Independence Co e Artelo Biosciences Inc
Artelo Biosciences Inc executives and stock owners
Artelo Biosciences Inc executives and other stock owners filed with the SEC include:
-
Gregory D. Gorgas,
Pres, CEO, CFO, Treasurer, Sec. & Director -
Jason H. Baybutt,
Sr. VP of Fin. -
Dr. Steven D. Reich,
Chief Medical Officer -
Peter Michael O'Brien,
Sr. VP of European Operations -
Dr. Andrew Yates Ph.D.,
Sr. VP, Chief Scientific Officer & Member of Scientific Advisor Board -
Randy Schreckhise,
VP of Fin. & Operations -
Donald T Netter,
Director -
Brian Schlier,
Vice President -
James G Tatum,
Director -
John A Whritner,
Director -
John L Lahey,
Director -
Ira R Harkavy,
Director -
Inc. Lrta,,
10% owner -
Corp /De/Nasco Holdings, In...,
-
Steven B Lapin,
President & COO -
H William Smith,
V.P., Gen. Counsel & Secretary -
W Phillip Niemeyer,
Vice President-Prod. Coord. -
Dean T Johnson,
Chief Financial Officer -
Corp /De/ Geneve,
10% owner -
John Joseph Crawford,
Director -
Sharon M Oster,
Director -
Douglas Blayney,
Director -
Connie Matsui,
Director -
Peter Michael O'brien,
-
Steven Kelly,
Director -
John W Beck,
-
Georgia Erbez,
-
Robert Martin Emanuele,
Director -
Gregory Reyes,
Director -
Tamara A Favorito,
Director -
Gregory D. Gorgas,
Pres, CEO, CFO, Treas & Sec